STUDY QUESTION: Is pre-ovulatory endometrial thickness (EMT) in women with unexplained subfertility undergoing IUI with ovarian stimulation (OS) associated with pregnancy chances?
Introduction
IUI with ovarian stimulation (IUI-OS) is perceived as a simple, noninvasive and non-expensive first-line treatment for women diagnosed with unexplained or mild male subfertility (Ombelet et al., 2008) . The most frequently used drugs for OS are anti-estrogens, such as clomiphene citrate (CC), aromatase inhibitors, such as letrozole and anastrozole, or gonodotrophins, such as HMG purified urinary FSH (uFSH) or recombinant FSH (rFSH). These drugs not only stimulate the growth of multiple follicles, but also proliferate the endometrium. The effect of this proliferation on the chances of conception is unclear.
Data on endometrial thickness (EMT) and pregnancy rates are scarce and conflicting. In some small retrospective cohort studies evaluating EMT in women undergoing IUI-OS with CC (N = 81), HMG (N = 24 and N = 112) or both (N = 81) a thin endometrium was associated with lower chances of conception and when the endometrium measured <6 to <8 mm conceptions did not occur at all (Dickey et al., 1993a; Isaacs et al., 1996; Reuter et al., 1996; Warrington et al., 2008) . In one of the studies in which HMG was given (N = 112), 35 of the total of 38 pregnancies (91%) originated in cycles with an EMT of ≥10 mm (Isaacs et al., 1996) . Similarly, a prospective study analyzing 270 women undergoing IUI-OS with CC, HMG and the combination of both found no pregnancies when the endometrium was below 6 mm (Dickey et al., 1993b) . In contrast, a prospective cohort study of 593 IUI-OS cycles with gonadotrophins found no correlation between EMT and cumulative pregnancy rate after three treatment cycles (De Geyter et al., 2000) . Another prospective study evaluating 168 women treated with CC observed no difference in EMT in women who did or did not conceive (Kolibianakis et al., 2004) .
In some studies OS with CC resulted in a thinner EMT than in natural cycles (Nakamura et al., 1997; Dehbashi et al., 2003; Haritha and Rajagopalan, 2003) or than in cycles stimulated with HMG (Gonen and Casper, 1990) . A review that evaluated EMT values in letrozole and CC cycles in women with unexplained subfertility found no evidence of a difference in EMT (Liu et al., 2014) . This review did not include comparisons with other stimulating drugs, for example gonadotrophins.
Since the association between EMT and pregnancy rates and the interaction between type of drug and EMT in women undergoing IUI-OS has not been assessed systematically, the aims of the present systematic review and meta-analysis were to assess first whether EMT is associated with pregnancy rates and second whether the type of drug affects EMT in women undergoing IUI-OS.
Materials and Methods
Our review followed the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analysis) guidelines for reporting. A medical librarian (J.L.) performed a comprehensive literature search in OVID MEDLINE, OVID EMBASE and the non-MEDLINE subset of PubMed from inception to 28th June 2016, to identify publications on EMT and pregnancy rates after IUI-OS. The search strategy, using both text words and MESH/ Emtree terms, consisted of two parts. The first was a search for EMT combined with terms for IUI, ART, CC, subfertility or spontaneous pregnancy.
The second was a search for prognostic studies on pregnancy success using IUI alone or IUI-OS. This enables the retrieval of papers that mention EMT in the full text but not in the title or abstract.
The MEDLINE search is shown in Supplementary Table S1 . We used no language or other restrictions. The search included an iterative process to refine the search strategy through adding search terms to identify new relevant citations, i.e. via reference and citation checking of relevant trials in Web of Science. We imported and de-duplicated the retrieved bibliographic records using EndNote ® X7.5 software (Thomson Reuters, New
York, NY, USA). Two reviewers (M.v.V. and N.W.) independently screened titles and abstracts of the identified studies and read the full articles for final inclusion. The reviewers checked cross references of the detected articles. The reviewers extracted the data from the included articles by using standardized data extraction forms. To assess study quality we used the risk of bias in nonrandomized (Sterne et al., 2016 ) assessment tool checklist for observational studies and the risk of bias assessment tool for RCTs (Cochrane Handbook) ( Table I) . We then extracted study data and if data were missing, we contacted authors by email. Disagreement between the reviewers was resolved through discussion with a third reviewer (M.v.W.). Risk of bias per study was expressed in the forest plots as colored dots, with red dots meaning high risk of bias, yellow unclear risk of bias and green low risk of bias. Pooled evidence was scored using Grade Profiler 3.6.1 as very low, low, moderate or high.
We included RCTs and cohort studies evaluating pregnancy rates after IUI-OS in women with unexplained infertility or mild male infertility. In case of randomized cross-over trials, we only used pre-cross-over data. Studies had to compare CC, aromatase inhibitors (letrozole and anastrozole), gonadotrophins or any combination of these drugs with each other or with any combination thereof and to report on pre-ovulatory EMT and/or EMT in pregnant and non-pregnant women. There was no limit for female age. The articles had to be written in English with full text available. We excluded trials in which estrogen was added to OS with CC.
We extracted data on ongoing pregnancy and clinical pregnancy. We defined ongoing pregnancy as a fetal heartbeat seen on ultrasound by 12 weeks of gestation and clinical pregnancy as a vital pregnancy seen on ultrasound. We registered all outcomes per woman. We extracted the mean EMT and SDs from the studies. In case the SE was provided, we calculated the SD ( = × √n SD SE ). We used Review Manager software to calculate mean differences (MD) with 95% CIs using a fixed model. In case of statistical heterogeneity above an I 2 of 50%, we considered the random effect model as the primary model. We performed a meta-regression analysis to evaluate whether there were differences between the cohort studies and the randomized studies and to evaluate if the drugs interacted with the estimated effect of EMT. As no cut-off values for EMT were available, the pre-planned summary receiver operating characteristic (sROC) curve to assess the accuracy of EMT in the prediction of pregnancy could not be made (Reitsma et al., 2005) .
Results
The electronic search revealed 1563 articles, of which we selected 110 articles for full reading after screening the title and abstract. After reading the full text, we excluded 87 studies (Fig. 1 ). Checking of cross references revealed two other studies. The characteristics of the 23 included studies are listed in Table II . There were 17 RCTs and 6 cohort studies comprising a total of 3846 women. The average quality of the studies was rated low to moderate. The largest study included 446 women (De Geyter et al., 2000) and the smallest study 30 women (Sipe et al., 2006) . Two studies reported live birth rates (Revelli et al., 2006; Sipe et al., 2006) , five trials reported pregnancy rates without defining the type of pregnancy, but since ultrasound findings were available we interpreted pregnancy outcomes as clinical pregnancy rates (Al-Fozan et al., 2004; Barroso et al., 2006; Akbary-Asbagh et al., 2007; Badawy et al., 2009 Badawy et al., , 2010 . All other studies reported clinical pregnancy rates. Since ongoing pregnancy rates were not available, we used clinical pregnancy rates as the outcome measure. In three studies data on EMT and pregnancy were available in the articles (Tsai et al., 2000; Esmailzadeh and Faramarzi, 2007; Bensdorp et al., 2015) . We contacted the authors of the remaining studies to provide the missing data on the EMT in pregnant and non-pregnant women, and four of them were able to supply these data (De Geyter et al., 2000; Revelli et al., 2006; Fouda and Sayed, 2011; Asante et al., 2013) . Five of these seven studies were cohort studies and two were RCTs. We asked all authors if they could provide the number of pregnant and non-pregnant women above and below a certain EMT cut-off value. None of the studies could provide these data and therefore ROC curve analysis was not feasible. We cannot exclude that cycles were canceled when a low EMT was measured. We assume this was not common practice as none of the studies mentioned canceling a cycle on the basis of EMT.
In all 23 studies data on type of drug and EMT were available. Six of these studies were cohort studies of which two studies evaluated CC, one study evaluated uFSH and one study evaluated CC combined with HMG. One comparative cohort study compared CC with gonadotrophins, another compared letrozole plus FSH with FSH.
The other 17 studies were RCTs. One RCT compared CC with gonadotrophins, five compared CC with letrozole, eight compared CC plus gonadotrophins with letrozole (or anastrozole), two compared letrozole with gonadotrophins and one compared rFSH with uFSH. All studies used HCG-injections to trigger ovulation. Five studies used a form of luteal phase support, either by administering progesterone suppository or injections (Barroso et al., 2006; Revelli et al., 2006; Badaway et al., 2009 Badaway et al., , 2010 Zadehmodares et al., 2012) .
EMT in pregnant versus non-pregnant women
The seven studies (two RCTs and five cohorts) from which we could extract mean EMT and corresponding SDs for pregnant and nonpregnant women are summarized in Table III . A total of 365 women became pregnant and 1160 women did not. Six studies found no statistical evidence of a difference between pregnant and non-pregnant women and one study observed a significantly thicker EMT in pregnant women (Esmailzadeh and Faramarzi, 2007) . Women who conceived had on average a thicker EMT than women who did not conceive (MD: 0.48, 95% CI: 0.18 to 0.77; I 2 = 73%). Using a random effect model the difference was no longer statistically significant (MD: 0.51, 95% CI: −0.05 to 1.07; I 2 = 74%) (Fig. 2) .
To overcome the statistical heterogeneity across studies, we also performed a sensitivity analysis leaving out the one study that found a significant difference between groups (Esmailzadeh and Faramarzi, 2007) . The MD was not statistically significant (MD: 0.25, 95% CI: −0.05 to 0.56; I 2 = 0%) for pregnant versus non-pregnant women.
Meta-regression did not indicate any difference in findings between the two RCTs and five cohort studies (P = 0.41). There was also no indication of a difference between treatment groups (P = 0.79). The study of Mitwally and Casper (2003) contained a third treatment group: 18 women received CC+FSH; EMT for this group was (mean(SD)) 8.0 (2). ***
EMT for CC versus gonadotrophins
Pooling the data of one cohort study and one RCT that compared CC with gonadotrophins, suggested that women treated with CC had a slightly thinner EMT than women treated with gonadotrophins (N = 383, MD: −0.33, 95% CI: −0.64 to −0.01; I 2 = 0%) (Fig. 3) .
EMT for CC versus letrozole and CC plus gonadotrophins versus letrozole
We found five studies that compared CC and letrozole, all RCTs. The pooled data suggested that women treated with CC had a significantly thinner EMT than women treated with letrozole (N = 1087; MD: 1.14, 95% CI: 0.78-1.51; I 2 = 86%). Using a random effect model the difference was no longer statistically significant (MD: −0.84, 95% CI: −1.97 to 0.28; I 2 = 86%).
We found nine studies that compared CC plus gonadotrophins with letrozole, eight RCTs and one cohort. The pooled data suggested that women treated with the combination of CC plus gonadotrophins had a significantly thinner EMT than women treated with letrozole (N = 1010; MD: −0.78, 95% CI: −0.99 to −0.57; I 2 = 84%).
Using a random effect model the difference was still statistically significant (MD: −0.79, 95% CI: −1.37 to −0.20; I 2 : = 84%) (Fig. 4) .
EMT for letrozole versus gonadotrophins
We found two studies that compared letrozole with gonadotrophins. Women treated with letrozole had a significantly thinner endometrium than women treated with gonadotrophins (N = 130; MD: −1.31, 95% CI: −2.08 to −0.53; I 2 = 0%) (Fig. 5) .
Discussion
In this meta-analysis we found no evidence for an association between EMT and pregnancy rates. Women treated with CC had a marginally thinner EMT than women treated with gonadotrophins. There was no evidence for a difference in EMT between CC and letrozole. combination of CC plus gonadotrophins resulted in a slightly thinner endometrium than letrozole, and letrozole alone resulted in a slightly thinner EMT than gonadotrophins alone. Some limitations of this review need to be addressed. The average quality of the included studies was low to moderate and mean EMT values differed across studies resulting in considerable statistical heterogeneity. Furthermore, EMT was not a primary outcome in any of the studies. It seems likely that EMT had not been measured in all women. The number of missing values for this outcome was not reported in the included studies. A limitation of our study is that the included studies did not report data on ongoing pregnancy rates and therefore we chose to use clinical pregnancy as outcome measure.
CC versus gonadotrophins, and letrozole versus gonadotrophins were compared in two studies only. Another limitation is the fact that we could not perform our planned sROC curve to determine the accuracy of EMT in the prediction of pregnancy, since the included studies did not deliver the necessary data.
Our review confirms the finding of one other review that evaluated EMT and pregnancy rates, but was limited to letrozole and CC cycles in women with unexplained subfertility (Liu et al., 2014 ). An association between EMT and pregnancy had been noted previously in an IUI population (Dickey et al., 1993a,b) : None of the women in this study had a pregnancy at an EMT below 6 mm. This finding was not confirmed by a study in a similar IUI population published a few years later, as these authors found pregnancies occurring at the lowest measured EMT of 4 mm (Hock et al., 1997) .
The small differences in EMT that we found in relation to type of drug are counterintuitive. Biologically it seems possible that OS with gonadotrophins alone results in thicker endometrium than stimulation with CC and stimulation with letrozole whereas the combination of CC with gonadotrophins gives thinner EMT than letrozole. We cannot exclude that the observed differences in EMT are due to heterogeneity across the included studies. Also, previous studies have reported that there can be an interobserver variability in measuring EMT by transvaginal ultrasound with a MD: 1.5 mm (Karlsson et al., 1994) . The small but statistically significant differences of <1.5 mm in our meta-analyses therefore are likely to be irrelevant clinically.
In IVF, the impact of the thickness of the proliferated endometrium on pregnancy rates has been studied in a review pooling the results of 13 studies that showed that no pregnancies occurred if the EMT was below 5 mm (Friedler et al., 1996) . Based on the Friedler et al. (1996) review, the National Institute for Health and Care Excellence fertility guideline recommends not to transfer a fresh embryo when the EMT is <5 mm (NICE, 2013) . A second, more recent systematic review pooling the results of 23 IVF studies, found that the chances of conception decreased if the EMT was ≤7 mm (odds ratio: 0.38, 95% CI: 0.09-1.5) compared to an EMT of over 7 mm (Kasius et al., 2014) .
We can only speculate why a thin endometrium is clinically more relevant in IVF cycles than in IUI. Possibly a thin endometrium developing under maximal OS conditions implies genuine diminished implantation potential compared to a thinner endometrium developing under milder stimulation conditions, as with IUI.
Since embryos do not develop well in high oxygen tensions, IVF laboratories keep oxygen concentrations around 5%. In endometrium of <7 mm, the functional layer is thin or absent, which causes the embryo to be closer to the uterine spiral arteries. This highly vascular layer may cause high oxygen concentrations in the basal endometrium and thus high oxygen concentrations too close to the implanting embryo (Casper, 2011) . A mere theoretical explanation could be that embryos developing in vivo are less susceptible to this higher oxygen exposure compared to embryos developing in vitro and thus, in IUI-OS, this effect is of less importance.
As the EMT does not seem to be a predictor for success in IUI-OS, it might be desirable to examine other biomarkers. It has been suggested that the subendometrial neovascularization measured by three-dimensional power Doppler ultrasound (3D PD-US) can predict pregnancy in women undergoing IUI. In a prospective study of 106 women undergoing ovulation induction and IUI, color Doppler ultrasound and a 3D PD-US examination were performed on the day of insemination. Pregnant women had higher endometrial and subendometrial blood flow parameters than women who did not conceive. Pregnancies did not occur when endometrial blood flow was not detected (Kim et al., 2010) . Another possible biomarker is the activin A concentration in uterine washing fluid. In a retrospective casecontrol study of 50 women treated with IUI-OS with FSH, pregnant women had significantly higher levels of activin A than non-pregnant women (Florio et al., 2010) . However before these new techniques are implemented, future research must clarify if 3D PD-US and measuring activing A levels is helpful in monitoring IUI-OS cycles.
Our results suggest that the differences in EMT between women who get pregnant and those that do not are too small to be useful as a tool to guide treatment for the individual woman. Therefore, canceling IUI cycles with thin endometrial lining because of the presumed negative effect of the thin EMT-of which we have found no proof-may lead to the very effect one tries to avoid, i.e. non-conception by the simple and easy to understand mechanism of not inseminating.
